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M
otor neurone disease (MND), or
amyotrophic lateral sclerosis (ALS),
is a progressive neurological
condition with no curative treatment and a
short prognosis – of two to five years from first
presentation. The cause is unknown for the
majority of patients, although in 5–10% of
them there is a family history. Recent
discoveries of new genes linked with MND
suggest that there may be increasing evidence
of a genetic cause, with an environmental
stimulus leading to the disease in susceptible
people.1 The only treatment available is
riluzole, which has been shown to slow the
rate of progression – but probably only by a
few months – over a period of two years.2
A palliative approach in MND
People with MND may present with variable
and mixed symptoms and signs, but there are
three main groups:
  People with ALS – with a mixed pattern of
upper and lower motor neurone nerve
damage, leading to weakness, wasting and
increased reflexes
  People with progressive bulbar palsy – with
primarily speech and swallowing issues
  People with progressive muscular atrophy –
with predominantly lower motor neurone
damage and increasing weakness and
flaccidity of the legs.
However, as the disease progresses, these
different patient groups may develop
symptoms and signs in all body areas. Patients
may rarely present with respiratory muscle
weakness, leading to respiratory failure.
As there is no cure for MND, it can be argued
that palliative care is appropriate from the
time of diagnosis, especially as the average
time between symptom onset and diagnosis is
ten months (many patients are already
severely disabled at diagnosis). Figure 1 shows
the role of a palliative approach in MND from
diagnosis to bereavement and the changes in
care requirements as the disease progresses.3
In accordance with the WHO definition of
palliative care,4 the aims of care for people
with MND should be to reduce the effects of
the disease on the patient and their family;
maintain the patient’s abilities for as long as
possible; and enable the patient and family to
live as full a life as possible.
Holistic palliative care for MND patients
and their families includes various aspects,
which are outlined below. Symptoms need to
  Motor neurone disease (MND) is a progressive neurological
condition with no cure and a short prognosis. Palliative care
involvement is therefore appropriate from the time of diagnosis.
  The symptoms of MND, which are varied and will worsen as the
disease progresses, should be managed appropriately.
  The psychosocial care needs of patients and their families or carers
should be addressed, including when there are concerns regarding
a possible genetic cause of the disease.
  The involvement of the specialist palliative care team may be
episodic, occuring at times of change, crisis or decision-making; 
for example, at diagnosis, when discussing gastrostomy or
ventilatory support, when there are cognitive changes and at the
end of life.
  End-of-life care planning – and reassurance that, with good
palliative care, death is usually peaceful – are a crucial part of care.
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be carefully assessed and the psychosocial
aspects need to be considered at all times.5
Symptom management
Symptom burden
MND patients will have many symptoms and
these will vary from person to person. The
burden will increase as the disease progresses,5
the most common symptoms being:
dysphagia (87% of patients), dyspnoea (85%
of patients), weight loss (84% of patients),
speech problems (74% of patients), pain (73%
of patients), constipation (53% of patients),
drooling (23% of patients) and emotional
lability (23% of patients).6
Pain 
Pain is common in MND and may be due to:
  Musculoskeletal pain – from changes
around joints because of altered muscle
tone, causing joint pain and/or stiffness 
  Cramp – from increased muscle tone,
especially following upper motor neurone
damage
  Skin pressure pain – from reduced changes
of position or immobility.
Careful positioning, physiotherapy and
occupational therapy should all be considered.
Specific medication – such as non-steroidal
anti-inflammatory drugs for joint pain or
antispasmodic medication for cramp – can be
helpful. Many patients with skin pressure pain
are helped by regular analgesia; they will start
on simple analgesics, but many may require
opioids.7 [ref changed from 5 to 7; correct?]
Studies have shown that morphine can be
used both effectively and safely in MND.8
Dysphagia
As bulbar muscles weaken, swallowing can be
affected, as there is reduced ability to chew
food, move the bolus back within the mouth
and swallow safely. Careful feeding, changing
the consistency of food (to that of custard)
and allowing time to eat are all helpful.
However, many patients may need to consider
gastrostomy – either percutaneous endoscopic
gastrostomy (PEG) or percutaneous
radiological gastrostomy (PRG).9
Careful discussion is necessary about the
insertion of a gastrostomy. It will enable to
continue nutrition and often improve quality
of life, but there is little evidence that it will
prolong life. The associated risks increase as
respiratory function reduces, particularly with
PEG insertion, where morbidity and mortality
increase if the forced vital capacity is below
50% of the expected value. Discussion is
therefore needed before swallowing is greatly
affected and thus before the patient is really
aware of the problems they are going to face.10
Drooling
A significant problem associated with
dysphagia is drooling; as the patient swallows
less saliva than usual, it collects in the mouth
and dribbles out. Good oral hygiene is crucial
and some drugs may help: anticholinergic
medication (such as sublingual or transdermal
hyoscine), antidepressants (such as
amitriptyline) or botulinum toxin injected
into the salivary glands.11
Respiratory issues
As respiratory muscle and diaphragmatic
function reduces, patients may become
breathless or develop symptoms of respiratory
failure (particularly at night). Symptoms will
include orthopnoea, vivid dreams and
nightmares, multiple arousals, morning
headache, anorexia and generally feeling
unwell. Careful assessment of respiratory
function is essential in the ongoing care of the
MND patient and respiratory support may
need to be considered.12 
In the UK, the National Institute for Health
and Care Excellence (NICE) has produced
 Figure 1. A palliative
approach in motor
neurone disease
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guidelines for the monitoring and assessment
of respiratory function, and suggests
considering non-invasive ventilation (NIV) in
symptomatic patients.13 Although there is
evidence that NIV will extend life,14 the disease
will continue to progress, which entails the
possibility of increasing disability, increasing
dependency on NIV and decreasing quality of
life. The NICE guidelines specify that, during
assessment for and when starting NIV, end-of-
life issues – including the withdrawal of NIV at
the end of life – should be discussed.13
Tracheostomy ventilation may be an option
for some patients, but there are even greater
ethical issues than with NIV. The use of
tracheostomy ventilation varies greatly,
within Europe and globally.
Psychosocial aspects of care
Psychological support
People with MND must cope with multiple
losses – of their abilities, cognition, emotions –
as well as face many difficult symptoms and
increasing dependency.15 They may have
specific concerns about the diagnosis – the
general media and the internet often
emphasise the distress associated with MND
and exacerbate the fear of choking to death.
There may be particular issues for people with
familial MND, as they may have memories of
MND and deaths in their family and worry
about their children. To allow these issues to
be expressed, careful listening and support are
crucial. Early involvement of palliative care
will increase the chance of the patient still
being able to express their concerns easily,
before communication aids are needed.
Family concerns
The families and close carers of people with
MND may have similar issues – experience of
multiple losses, communication problems as
the person’s speech deteriorates – but also
issues that are particular to them – their own
fears and emotions, financial concerns.16
Psychosocial support needs to be routinely
offered to MND family carers throughout the
illness trajectory. Family carers who get timely
support from palliative care services will have
better bereavement outcomes.17
Spiritual issues
The spiritual concerns of patients, families
and carers (including ‘why me?’ and concerns
and fears about death and dying) may deepen
as the disease progresses. Together with
cultural and religious issues, these concerns
should be acknowledged and appropriate
support should be provided.18
A multidisciplinary approach 
The multiple issues and concerns outlined
above show that a multidisciplinary approach
is required to managed MND. A team of
appropriate health- and social care
professionals is needed to assess and address
all aspects of care. To ensure care is
coordinated and patients and families feel
supported, it is important that the team
regularly works with MND patients, has the
necessary experience and knowledge of the
issues involved, and that its members work
together. The wider caring team, including
family members providing day-to-day
personal care, also needs ongoing support, as
the care of a person with MND can be
physically and emotionally demanding.16
This team approach can be complex, as
many different disciplines may become
involved: neurology, rehabilitation,
gastroenterology (if gastrostomy is being
considered), respiratory (if NIV is used), as well
as primary care and palliative care. There may
be issues within and between the different
teams involved, as these may have different
attitudes and philosophies, and it is important
that there is awareness of these issues.19
When is palliative care appropriate?
The provision of palliative care for people with
MND varies, both between and within
countries. In the UK, there is evidence that
specialist palliative care services may be less
involved in the early stages of the disease now
than they were in the past.20 However, there is
increasing evidence that a wider
 Figure 2. Involvement




A. The traditional model of late involvement of specialist palliative services
B. The model of early and increasing involvement of specialist palliative services
C. The model of dynamic involvement of specialist palliative services based on trigger points
Neurological and medical specialties
Neurological and medical specialties











[Does Figure 2 need a reference or credit?]
289EUROPEAN JOURNAL OF PALLIATIVE CARE, 2013; 20(6)
www.ejpc.eu.com Clinical  management
multidisciplinary team approach is effective,
and may even extend patients’ lives.21
Palliative care needs may vary through the
disease trajectory and the involvement of
specialist teams may be episodic, occuring at
times of change, crisis or decision-making; for
example, at diagnosis, when discussing
gastrostomy or ventilatory support, when
there are cognitive changes and at the end of
life (see Figure 2).22
When more complex interventions are
introduced, there may be new issues arising.
For example, when gastrostomy or NIV are
considered, there may be an emphasis on the
discussion regarding the intervention and
hence less discussion on how to manage the
patient’s progressive deterioration. This may
in turn reduce everybody’s awareness of the
general deterioration and, crucially, of the
need to discuss end-of-life issues. This has
been addressed in the NICE guidelines, which
say that end-of-life issues should be discussed
when NIV is started and also when it is
increasingly used as the patient approaches
the end of life.13
Certain signs suggest that end-of-life care is
needed, in patients with neurological disease
in general (dysphagia, cognitive decline,
repeated infections, weight loss, marked
decline in condition) and in those with MND
in particular (breathlessness/respiratory
failure, swallowing issues, cognitive change,
weakness).23 These signs should act as triggers
to encourage professionals to discuss end-of-
life issues with patients and families and help
them to start planning, looking at:
  Preferences for place of care and death
  Provision of anticipatory medications so
that these are readily available if needed
quickly (as suggested in the UK by the MND
Association in its ‘Just in case kit’)24
  Advance care planning (advance directives,
advance decision to refuse treatment,
defining a proxy for decisions, and so on).
Conclusion 
In any care setting, palliative care is essential
for patients with MND and families to ensure
their symptoms and issues are clearly
identified and appropriately managed by a
multidisciplinary team. Sensitive end-of-life
discussions and planning will help as the end
of life approaches. Many patients and families
fear a distressing death accompanied by pain,
choking and breathlessness. However, with
good palliative care, death in MND patients is
usually peaceful.25,26 Reassuring patients and
families is a crucial part of care.
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